Sk Biopharmaceuticals Co Ltd Asset Resilience Ratio
Sk Biopharmaceuticals Co Ltd asset resilience ratio. Sk Biopharmaceuticals Co Ltd (326030) has an Asset Resilience Ratio of 0.14% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 326030 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Sk Biopharmaceuticals Co Ltd (2016–2025)
Asset resilience ratio of Sk Biopharmaceuticals Co Ltd from 2016 to 2025. This chart shows how Sk Biopharmaceuticals Co Ltd's Asset Resilience Ratio has changed over time. Read Sk Biopharmaceuticals Co Ltd total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Sk Biopharmaceuticals Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Sk Biopharmaceuticals Co Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩1.87 Billion | 0.14% |
| Total Liquid Assets | ₩1.87 Billion | 0.14% |
Asset Resilience Insights
- Limited Liquidity: Sk Biopharmaceuticals Co Ltd maintains only 0.14% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Sk Biopharmaceuticals Co Ltd Industry Peers by Asset Resilience Ratio
Compare Sk Biopharmaceuticals Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Sk Biopharmaceuticals Co Ltd Asset Resilience Ratio by Year (2016–2025)
Sk Biopharmaceuticals Co Ltd asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Sk Biopharmaceuticals Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.14% | ₩1.71 Billion ≈ $1.16 Million |
₩1.20 Trillion ≈ $812.08 Million |
-0.02pp |
| 2024-12-31 | 0.16% | ₩1.68 Billion ≈ $1.14 Million |
₩1.04 Trillion ≈ $702.63 Million |
-0.03pp |
| 2023-12-31 | 0.20% | ₩1.42 Billion ≈ $961.23K |
₩723.17 Billion ≈ $490.08 Million |
-30.12pp |
| 2022-12-31 | 30.32% | ₩201.39 Billion ≈ $136.48 Million |
₩664.24 Billion ≈ $450.15 Million |
+13.48pp |
| 2021-12-31 | 16.84% | ₩108.42 Billion ≈ $73.47 Million |
₩643.65 Billion ≈ $436.19 Million |
-48.86pp |
| 2020-12-31 | 65.70% | ₩328.66 Billion ≈ $222.73 Million |
₩500.24 Billion ≈ $339.01 Million |
+43.24pp |
| 2019-12-31 | 22.46% | ₩31.23 Billion ≈ $21.17 Million |
₩139.07 Billion ≈ $94.25 Million |
+20.12pp |
| 2018-12-31 | 2.34% | ₩2.24 Billion ≈ $1.52 Million |
₩95.54 Billion ≈ $64.74 Million |
-37.39pp |
| 2017-12-31 | 39.73% | ₩39.08 Billion ≈ $26.48 Million |
₩98.37 Billion ≈ $66.66 Million |
-27.41pp |
| 2016-12-31 | 67.14% | ₩130.18 Billion ≈ $88.22 Million |
₩193.89 Billion ≈ $131.40 Million |
-- |
About Sk Biopharmaceuticals Co Ltd
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, wh… Read more